Upstream patents and public health: The case of genetic testing for breast cancer

Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Volumn , Issue , 2006, Pages 327-345

  Orsi, Fabienne ^a   Sevilla, Christine ^b   Coriat, Benjamin ^a  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878928279     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511493232.011     Document Type: Chapter

References (37)

1. Académie des Sciences (1992), La brevetabilitédu génome, Report no. 32, Editions Techniques et Documents, Paris. Armstrong, K., J. Stopfer, K. Calzone, G. Fitzgerald, J. Coyne, and B. Weber
2. Académie des Sciences (2002), “What does my doctor think? Preferences for knowing the doctor’s opinion among women considering clinical testing for BRCA1/2 mutations,” Genetic Testing, 6, 115–18.
3. Arrow, K. (1962), “Economic welfare and allocation of resources for inventions,” in R. R. Nelson (ed.), The Rate and Direction of Inventive Activity, Princeton University Press, Princeton, NJ, 609–25.
4. Benowitz, S. (2003), “European groups oppose Myriad’s latest patent on BRCA1,” Journal of the National Cancer Institute, 95, 8–9.
5. Brower, V. (1997), “Testing, testing… testing?,” NatureMedicine, 3, 131–2.
6. Butler, D., and S. Goodman (2001), “French researchers take a stand against cancer gene patent,” Nature, 413, 95–6.
7. Cassier, M., and J. P. Gaudillière (2000a), “Le génome: bien privéou bien commun?,” Biofutur, 204, 26–30.
8. Cassier, M., and J. P. Gaudillière (2000b), “Recherche, médecine et marché: la génétique du cancer du sein,” Sciences Sociales et Santé, 18, 29–49.
9. Coriat, B., and F. Orsi (2002), “Establishing a new intellectual property rights regime in the United States: origins, content, problems,” Research Policy, 31 (8-9), 1491–507.
10. Dasgupta, P., and P. A. David (1994), “Toward a new economics of science”, Research Policy, 23 (5), 487–521.
11. Eisenberg, R. S. (1987), “Property rights and the norms of science in biotechnology research,” Yale Law Journal, 97 (2), 177–231.
12. Eisenberg, R. S. (2000), “Analyze this: a law and economics agenda for patent system”, Vanderbilt Law Review, 53 (6), 2081–98.
13. Findlay, S. D. (2001), “Direct-to-consumer promotion of prescription drugs: economic implications for patients, payers and providers,” Pharmacoeconomics, 19, 109–19.
14. Gollust, S. E., S. C. Hull, and B. S. Wilfond (2002), “Limitations of directto- consumer advertising for clinical genetic testing,” Journal of the American Medical Association, 288, 1762–7.
15. Harnett, C. J. (1994), “The Human Genome Project and the downside of federal technology transfer,” Risk: Health, Safety and Environment, Spring.
16. Heller, M.A., and R. S. Eisenberg (1998), “Can patent deter innovation? The anticommons tragedy in biomedical research,” Science, 280, 698–701.
17. Huiart, L., F. Eisinger, D. Stoppa-Lyonnet, C. Lasset, C. Nogues, P. Vennin, H. Sobol, and C. Julian-Reynier (2002), “Effects of genetic consultation on perception of a family risk of breast/ovarian cancer and determinants of inaccurate perception after the consultation,” Journal of Clinical Epidemiology, 55, 665–75.
18. Kaufert, P. A. (2000), “Health policy and the new genetics,” Social Science and Medicine, 51, 821–9.
19. Kitch, T. (1977), “The nature and function of the patent system,” Journal of Law and Economics, 20, 265–90.
20. Merges, R. P., and R. R. Nelson (1994), “On limiting or encouraging rivalry in technical progress: the effect of patent scope decisions,” Journal of Economic Behavior and Organization, 25, 1–24.
21. Merton, R. (1973), The Sociology of Science: Theoretical and Empirical Investigation, University of Chicago Press, Chicago.
22. Morgan, S., J. Hurley, F. Miller, and M. Giacomini (2003), “Predictive genetic tests and health system costs,” Canadian Medical Association Journal, 168, 989–91.
23. Nelson, R. R. (1959) “The simple economics of basic scientific research,” Journal of Political Economy, 67, 297–306.
24. Nelson, R. R. (2003), The Market Economy and the Scientific Commons, working paper, School of International and Public Affairs, Columbia University, New York.
25. Orsi, F. (2002), “La constitution d’un nouveau droit de proprié téintellectuelle sur le vivant aux Etats-Unis: origine et signification économique d’un dépassement de frontiè re,” Revue d’Economie Industrielle, 99 (2), 65–86.
26. Press, N. A., Y. Yasui, S. Reynolds, S. J. Durfy, and W. Burke (2001), “Women’s interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations,” American Journal of Medical Genetics, 99, 99–110.
27. Rai, A. K. (2001), “Fostering cumulative innovation in the biopharmaceutical industry: the role of patents and antitrust,” Berkeley Technology Law Journal, 16, 813–53.
28. Rai, A. K., and R. S. Eisenberg (2003), “Bayh–Dole reform and the progress of biomedicine,” Law and Contemporary Problems, 66, 289–313.
29. Scherer, F. M., and J. Watal (2001), Post-Trips Options for Access to Patented Medicines in Developing Countries, Working Paper WG4, Center for Metropolitan History, London.
30. Sevilla, C., P. Bourret, C. Noguè s, J. P. Moatti, H. Sobol, Groupe Génétique et Cancer, and C. Julian-Reynier (2004), “L’offre de tests de prédisposition génétique au cancer du sein ou de l’ovaire en France,” Médecine/Sciences, 20, 788–92.
31. Sevilla, C., C. Julian-Reynier, F. Eisinger, D. Stoppa-Lyonnet, B. Bressac de Paillerets, H. Sobol, and J. P. Moatti (2003), “The impact of gene patents on the cost-effective delivery of care: the case of BRCA1 genetic testing,” International Journal of Technology Assessment in Health Care, 19, 287–300.
32. Sevilla, C., J. P. Moatti, C. Julian-Reynier, F. Eisinger, D. Stoppa-Lyonnet, B. Bressac de Paillerets, and H. Sobol (2002), “Testing for BRCA1 mutations: a cost-effectiveness analysis,” European Journal of Human Genetics, 10, 599–606.
33. USPTO (2001), “Utility examination guidelines,” Federal Register, 66, 1092–9.
34. Wadman, M. (2001), “Testing time for gene patent as Europe rebels,” Nature, 413, 443.
35. Wazana, A. (2000), “Physicians and the pharmaceutical industry: is a gift ever just a gift?,” Journal of the American Medical Association, 283, 373–80.
36. Williams-Jones, B. (2002), “History of a gene patent: tracing the development and application of commercial BRCA testing,” Health Law Journal, 10, 121–44.
37. Wolfe, S. M. (2002), “Direct-to-consumer advertising – education or emotion promotion?,” New England Journal of Medicine, 346, 524–6.